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Abstract
Background—Historically, foreign-born individuals in the US have had an elevated risk of dying 
from gastric cancer when compared to US-born individuals. This is primarily due to factors that 
occur prior to their immigration to the US, including diet and underlying risk of H. pylori 
infection.
Methods—National mortality data from 2005 to 2014 were obtained from the CDC’s National 
Center for Health Statistics. Annual population estimates were obtained from the US Census 
Bureau’s American Community Survey for foreign-born and US-born persons. Age-adjusted 
gastric cancer mortality rates and rate ratios (RR) were calculated stratified by birth place, age, 
race/ethnicity, and geographic location.
Results—From 2005 to 2014, 111,718 deaths from malignant gastric cancer occurred in the US, 
of which 24,583 (22%) occurred among foreign-born individuals. Overall, foreign-born 
individuals had higher mortality rates compared with US- born individuals (RR 1.82; 95% CI 1.80, 
1.85) and this difference remained after stratifying by sex, age, and geographic location. However, 
this finding was primarily driven by the low rate of gastric cancer mortality among US-born 
whites, with similar mortality rates observed among all other foreign-born and US-born groups. 
Gastric cancer mortality rates significantly decreased during the study period overall (AAPC 
− 2.50; 95% CI − 3.21, − 1.79) with significant declines observed among US-born (AAPC − 2.81; 
95% CI − 3.55, − 2.07) and the foreign-born (AAPC − 2.53; 95% CI − 3.20, − 1.86) population.
Conclusions—Efforts directed at reducing the prevalence of gastric cancer risk factors could 
help reduce the elevated burden observed among foreign-born individuals and US-born minority 
groups.
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Introduction
Gastric cancer is the second leading cause of cancer-related deaths worldwide, with 984,00 
new cases and 841,000 deaths occurring annually [1]. While dietary factors, genetic 
susceptibility, and smoking can increase gastric cancer risk, most cases (89%) are attributed 
to H. pylori infection [2–4]. Worldwide, over half of the world’s population (4.4 billion) is 
infected with H. pylori, with the prevalence varying dramatically by geographic region 
[Africa (79.1%), Latin America (63.4%), Asia (54.7%), Europe (34.3–62.8%), and North 
America (37.1%)] [5]. In contrast to this distribution, almost 75% of gastric cancer cases 
occur in Asia, with over half of all gastric cancer patients coming from China, Japan, and 
Korea [1, 5].
In the United States (US), gastric cancer is less frequent, with 23,695 new cases and 11,330 
deaths occurring in 2015 [6]. Due to factors that occur prior to their immigration to the US 
(diet and underlying risk of H. pylori infection), foreign-born individuals in the US have an 
elevated risk of developing and dying from gastric cancer when compared to US-born 
individuals [7–9]. To address this issue, some groups are beginning to recommend H. pylori 
screening for first-generation immigrants who migrate from high burden countries [10]. To 
better address this health disparity, we utilized recent cancer mortality data to describe 
gastric cancer mortality among the foreign-born population.
Methods
Population-based mortality data from 2005 to 2014 were obtained from the National Center 
for Health Statistics (NCHS) for the 50 states and the District of Columbia. NCHS collects 
information on sex, race, ethnicity, place of birth, age at death, state of residence, and cause 
of death from death certificates filed in each state. Individuals who were born in one of the 
50 states, the District of Columbia, or the US territories were categorized as US-born. All 
other cases with recorded places of birth were categorized as foreign-born [11]. Deaths for 
malignant gastric cancer were selected using the International Classification of Disease 
version 10 (ICD-10) code C16 based on underlying cause of death. Cases with no recorded 
place of birth (1.11%) were excluded from all analyses.
Annual population estimates were obtained from the US Census Bureau’s American 
Community Survey (ACS). Annual ACS public-use microdata sample files were used to 
estimate the US-born and foreign-born population by age, race/ethnicity, sex, and census 
region using provided person weights.
Mortality data and population estimates from 2005 to 2014 were formatted using the 
Surveillance Epidemiology End Results Program SEER*Prep [12] software to create a 
SEER*Stat database [13]. We calculated age-adjusted mortality rates adjusting to the 2000 
US standard population. SEER*Stat was used to calculate mortality rate ratios (RR) by 
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nativity status, age, race/ethnicity, and geographic location. Joinpoint was used to calculate 
the average annual percent change (AAPC) from 2005 to 2014.
Results
From 2005 to 2014, 111,718 deaths from malignant gastric cancer occurred in the US, of 
which 24,583 (22%) occurred among the foreign-born population. Overall, foreign-born 
individuals had higher mortality rates when compared with US-born individuals (RR 1.82; 
95% CI 1.80, 1.85) and the differences remained after stratifying by sex, age, and 
geographic location (Table 1).
Foreign-born males who were non-Hispanic white (RR 2.01; 95% CI 1.95, 2.08) had higher 
mortality rates when compared with US-born non-Hispanic whites. In contrast, foreign-born 
men who were non-Hispanic black (RR 0.87; 95% CI 0.80, 0.94), non-Hispanic Asian/
Pacific Islander (RR 0.98; 95% CI 0.90, 1.07), and Hispanic (RR 0.99; 95% CI 0.94, 1.04) 
had a similar or lower mortality rates when compared to their US-born counterparts. Non-
Hispanic white (RR 1.91; 95% CI 1.84, 1.99), non-Hispanic Asian/Pacific Islander (RR 
1.25; 95% CI 1.13, 1.40) and Hispanic (RR 1.10; 95% CI 1.04, 1.16) foreign-born women 
had higher mortality rates compared to their US-counterparts, with no excess risk observed 
among foreign-born non-Hispanic blacks. When examined by race/ethnicity overall, the 
lowest mortality rates were observed among US-born non-Hispanic whites, with similar 
rates observed among all other US and foreign-born race/ethnicity groups (Fig. 1).
Gastric cancer mortality rates significantly decreased during the study period overall (AAPC 
− 2.50; 95% CI −3.21, − 1.79) with significant declines observed among US-born (AAPC 
− 2.81; 95% CI − 3.55, − 2.07) and the foreign-born (AAPC − 2.53; 95% CI − 3.20, − 1.86) 
population. With the exception of foreign-born Hispanics, cancer mortality rates 
significantly decreased among all racial/ethnic groups (Fig. 1).
Discussion
Foreign-born individuals in the US had a higher rate of gastric cancer mortality when 
compared to US-born individuals; however, this was primarily driven by the low rate of 
gastric cancer mortality observed among US-born whites. H. pylori is considered a 
necessary, but not sufficient cause for gastric cancer, and the most recent reviews of studies 
using sensitive assays for this bacterium conclude that at least 89% of such cancers are 
attributable to H. pylori infection [4]. Therefore, the elevated mortality rates observed 
among foreign-born individuals and US-born minority groups are likely reflective of 
elevated H. pylori infection rates in these populations, which have been previously 
documented [5, 14].
To reduce the burden of gastric cancer among foreign-born and US-born minority groups, 
efforts could be directed at reducing the prevalence of H. pylori, diet modification, and 
improvements in socioeconomic position and hygiene levels [3]. Recently published 
consensus guidelines recommended that “individuals who are first- generation immigrants 
from high prevalence areas be tested for H. pylori” [10]. The authors rated this as a strong 
recommendation based on moderate quality evidence. The authors also “suggested” that 
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Latino and African American racial or ethnic groups “may be” considered for H. pylori 
testing (a weak recommendation based on low quality evidence) due to their high risk of 
infection [10]. The authors strongly emphasized that testing methods which identify active 
infection, such as stool antigen testing and the urea breath testing, should be used and that 
serological testing should be discouraged. The recommendations also emphasize antibiotic 
treatment is needed for persons with active infection, and eradication in treated persons 
should be documented with follow-up testing. Increasing consumption of fruits, vegetables, 
and fiber while reducing the intake of foods that have been smoked, salted, or pickled can 
further reduce gastric cancer risk [2, 3]. Finally, as H. pylori infection generally occurs from 
interfamilial transmission during childhood, working to improve the socioeconomic position 
and hygiene levels of impacted populations can further reduce H. pylori’s burden among 
affected groups [2, 3, 5].
The significant declines in gastric cancer mortality observed among non-Hispanic whites, 
non-Hispanic blacks, and non-Hispanic APIs reflect global declines in gastric cancer as H. 
pylori prevalence continues to decline with improvements in socioeconomic status, hygiene 
levels, and healthcare access [1]. In contrast to global trends, in Mexico, the gastric cancer 
mortality rate has remained relatively stable since the 1990s [15]. As a majority of foreign-
born Hispanics are born in Mexico, the lack of decline observed among foreign-born 
Hispanics likely reflects these trends.
With the identification of specific high-risk groups (e.g., first-generation immigrants from 
China, Japan, or Korea) directly screening for gastric cancer may be appropriate and could 
lower mortality risk [4, 16]. In addition, studies conducted in high burden areas have found 
that H. pylori screening, treatment, and eradication can effectively reduce gastric cancer risk 
by 34% [17]. However, while gastric cancer screening programs have been successful in 
some Asian countries, very limited data exist on their utility in lower burden countries [18]. 
Currently, there is no evidence from randomized trials in the United States that demonstrate 
a decrease in mortality from direct screening using endoscopy for gastric cancer. This 
paucity of evidence, and the invasive nature of endoscopic testing, has led to this service not 
being regularly promoted in any population in this country [4]. While many studies have 
described the proper screening, management, and treatment of H. pylori [19, 20], future 
work could evaluate the efficacy of population-based H. pylori screening, management, and 
treatment in lower burden settings and among high-risk populations [3–5].
This study’s greatest strength is that it provides gastric cancer mortality rates by birth place, 
age, sex, race/ethnicity, and geographic region for the entire US population over the last 
decade. Lack of information on birthplace for foreign born was a limitation of the data used. 
Future work could utilize country specific information to identify countries with particular 
high gastric cancer mortality risk.
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Fig. 1. 
Average annual percent change in gastric cancer mortality rates by birth place and race/
ethnicity: United States 2005–2014. Gastric cancer was defined using ICD-10 code C16 
based on the underlying cause of death. AAPC average annual percent change, API Asian 
and Pacific Islander. *The AAPC is significantly different from 0 at alpha = 0.05
aGastric cancer was defined using ICD-10 code C16 based on the underlying cause of death. 
Average Annual Percent Change (AAPC) dAsian and Pacific Islander (API). *The AAPC is 
significantly different from 0 at alpha = 0.05.
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